ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008
WALTHAM, Mass., Aug 27, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Thomas Weisel Partners Healthcare Conference 2008 will be webcast live. The presentation is scheduled to begin at 11:30a.m. EDT on September3,2008, and will be given at the Four Seasons Boston hotel. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Information" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until September 10, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Produg (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis and Biogen Idec also are testing TAP compounds in the clinic, and a naked antibody is in clinical trials through the Company's collaboration with sanofi-aventis.
SOURCE: ImmunoGen, Inc.
Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
